GlassScriptPhysician profile
James M Brown
NPI 1205816550
$10,478.58
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,897 · 2020: $2,046 · 2021: $2,349 · 2022: $2,022 · 2023: $2,055 · 2024: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.94 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,361.05 | 2019-2024 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,318.03 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $985.92 | 2019-2023 | |
| Amarin Pharma, INC. | $980.59 | 2019-2022 | |
| Lilly USA, LLC | $793.06 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $571.41 | 2019-2023 | Repatha, Otezla |
| Allergan, INC. | $398.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.90 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $321.24 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $309.98 | 2019-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $304.19 | 2019-2022 | |
| Esperion Therapeutics, INC. | $272.82 | 2020-2023 | Nexletol |
| Glaxosmithkline, LLC. | $216.48 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $210.29 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $175.72 | 2023 | Gemtesa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.